The system assessment of infliximab in treatment of severe alcoholic hepatitis
10.3760/cma.j.issn.1673-4904.2014.12.013
- VernacularTitle:英夫利昔单抗治疗重症酒精性肝炎的系统评价
- Author:
Xiaojuan TIAN
;
Yuanhu GUO
;
Huiyan LI
- Publication Type:Journal Article
- Keywords:
Hepatitis,alcoholic;
Infliximab;
Drug evaluation
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(12):37-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematic review the clinical efficacy and safety of infliximab in treatment of severe alcoholic hepatitis (SAH).Methods The electronic database of PubMed,EMbase,Web of Science,OVID and Cochrane systematic review database,CBM disc and CNKI from building the database until March 2013 were retrieved.With SAH,severe alcoholic hepatitis,infliximab and tumor necrosis factor as key words or free words.Randomized-controlled trials (RCT) on infliximab in treatment of SAH was selected and analyzed by Meta analysis.Results Two RCTs was enrolled,included 56 SAH patients.Infliximab (10 mg/kg) combined with glucocorticoids (40 mg/d) might accelerate death because of the high prevalence of serious infections.Infliximab (5 mg/kg) combined glucocorticoids (40 mg/d) had more tolerability and improved patient's Maddrey scores significantly.Conclusions Existing clinical evidence suggest that it is short of evidence for the clinical efficacy and safety of infliximab.It need guide by large sample of clinically and different doses RCT.
